{"id":93127,"date":"2026-04-07T15:03:00","date_gmt":"2026-04-07T13:03:00","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=93127"},"modified":"2026-04-07T15:31:09","modified_gmt":"2026-04-07T13:31:09","slug":"andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/","title":{"rendered":"Andera Partners annonce l’acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration."},"content":{"rendered":"

Andera Partners annonce aujourd’hui que Gilead Sciences, Inc. (Nasdaq : GILD) a conclu un accord d\u00e9finitif en vue d’acqu\u00e9rir Tubulis GmbH, une soci\u00e9t\u00e9 de biotechnologie priv\u00e9e bas\u00e9e en Allemagne, en phase clinique, sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de conjugu\u00e9s anticorps-m\u00e9dicament (ADC) de nouvelle g\u00e9n\u00e9ration.<\/p>\n

L’acquisition \u00e9largit consid\u00e9rablement les capacit\u00e9s ADC de Gilead en y int\u00e9grant des actifs et des plateformes de nouvelle g\u00e9n\u00e9ration con\u00e7us pour d\u00e9livrer de mani\u00e8re plus s\u00e9lective divers agents de chimioth\u00e9rapie appel\u00e9s payload<\/i> <\/i>aux tumeurs et maximiser le b\u00e9n\u00e9fice pour les patients. Le principal produit de Tubulis, TUB-040, un ADC conjugu\u00e9 \u00e0 un inhibiteur de la topoisom\u00e9rase I (TOPO1i) ciblant NaPi2b, est actuellement en d\u00e9veloppement de phase 1b\/2 pour le cancer de l’ovaire r\u00e9sistant au platine et le cancer du poumon non \u00e0 petites cellules . Gilead acquerra \u00e9galement TUB-030, un ADC ciblant 5T4, qui a g\u00e9n\u00e9r\u00e9 des donn\u00e9es cliniques initiales prometteuses dans plusieurs types de tumeurs solides. Les programmes et plateformes de Tubulis pr\u00e9sentent un potentiel \u00e9tendu sur de multiples types tumoraux, en compl\u00e9mentarit\u00e9 avec l’expertise existante de Gilead en d\u00e9veloppement et commercialisation de produits innovants en oncologie.<\/p>\n

\u00ab<\/i> <\/i>D\u00e8s<\/i> <\/i>le<\/i> <\/i>d\u00e9part,<\/i> <\/i>nous<\/i> <\/i>avions<\/i> <\/i>la<\/i> <\/i>conviction<\/i> <\/i>que<\/i> <\/i>nos<\/i> <\/i>plateformes<\/i> <\/i>technologiques<\/i> <\/i>de<\/i> <\/i>conjugaison <\/i>pourraient<\/i> <\/i>avoir<\/i> <\/i>un<\/i> <\/i>impact<\/i> <\/i>majeur<\/i> <\/i>dans<\/i> <\/i>le<\/i> <\/i>domaine<\/i> <\/i>des<\/i> <\/i>ADC,<\/i> <\/i>et<\/i> <\/i>les<\/i> <\/i>donn\u00e9es<\/i> <\/i>initiales<\/i> <\/i>de<\/i> <\/i>TUB-040<\/i> <\/i>ont<\/i> <\/i>renforc\u00e9<\/i> <\/i>cette<\/i> <\/i>conviction \u00bb<\/i>, a d\u00e9clar\u00e9 Dominik Schumacher,<\/b> <\/b>PhD,<\/b> <\/b>Directeur G\u00e9n\u00e9ral<\/b> <\/b>et<\/b> <\/b>co-fondateur de<\/b> <\/b>Tubulis.<\/b> <\/b>\u00ab<\/i> <\/i>Rejoindre<\/i> <\/i>Gilead<\/i> <\/i>nous<\/i> <\/i>permet<\/i> <\/i>de<\/i> <\/i>b\u00e2tir<\/i> <\/i>sur<\/i> <\/i>ces<\/i> <\/i>fondations<\/i> <\/i>au<\/i> <\/i>sein<\/i> <\/i>d’une<\/i> <\/i>organisation<\/i> <\/i>dot\u00e9e<\/i> <\/i>d’une<\/i> <\/i>expertise<\/i> <\/i>scientifique<\/i> <\/i>approfondie, de<\/i> <\/i>capacit\u00e9s de<\/i> <\/i>d\u00e9veloppement mondiales<\/i> <\/i>et<\/i> <\/i>de<\/i> <\/i>l’envergure<\/i> <\/i>n\u00e9cessaire<\/i> <\/i>pour<\/i> <\/i>transformer<\/i> <\/i>l’innovation<\/i> <\/i>en<\/i> <\/i>m\u00e9dicaments<\/i> <\/i>destin\u00e9s<\/i> <\/i>aux<\/i> <\/i>patients<\/i> <\/i>du<\/i> <\/i>monde<\/i> <\/i>entier.<\/i> <\/i>Gr\u00e2ce<\/i> <\/i>\u00e0<\/i> <\/i>notre<\/i> <\/i>collaboration<\/i> <\/i>existante,<\/i> <\/i>Gilead<\/i> <\/i>a<\/i> <\/i>d\u00e9j\u00e0<\/i> <\/i>pu<\/i> <\/i>appr\u00e9cier<\/i> <\/i>le<\/i> <\/i>potentiel<\/i> <\/i>de<\/i> <\/i>nos<\/i> <\/i>technologies<\/i> <\/i>et,<\/i> <\/i>ensemble,<\/i> <\/i>nous<\/i> <\/i>sommes<\/i> <\/i>bien<\/i> <\/i>positionn\u00e9s<\/i> <\/i>pour<\/i> <\/i>acc\u00e9l\u00e9rer<\/i> <\/i>le<\/i> <\/i>d\u00e9veloppement<\/i> <\/i>de<\/i> <\/i>notre<\/i> <\/i>pipeline<\/i> <\/i>ADC.<\/i> <\/i>Je<\/i> <\/i>suis<\/i> <\/i>profond\u00e9ment<\/i> <\/i>reconnaissant<\/i> <\/i>envers<\/i> <\/i>l’\u00e9quipe<\/i> <\/i>Tubulis,<\/i> <\/i>notre<\/i> <\/i>Conseil<\/i> <\/i>d’administration,<\/i> <\/i>nos<\/i> <\/i>investisseurs<\/i> <\/i>et nos partenaires pour<\/i> <\/i>leur<\/i> <\/i>engagement et leur contribution<\/i> <\/i>\u00e0 ce jalon historique. \u00bb<\/i><\/p>\n

\u00ab Nous sommes extr\u00eamement fiers d’avoir soutenu Dominik et son \u00e9quipe depuis que nous avons men\u00e9 <\/i>le<\/i> <\/i>tour<\/i> <\/i>de<\/i> <\/i>S\u00e9rie<\/i> <\/i>B<\/i> <\/i>de<\/i> <\/i>Tubulis<\/i> <\/i>en<\/i> <\/i>2022.<\/i> <\/i>Cette<\/i> <\/i>acquisition<\/i> <\/i>t\u00e9moigne<\/i> <\/i>du<\/i> <\/i>potentiel<\/i> <\/i>des<\/i> <\/i>technologies<\/i> <\/i>et<\/i> <\/i>du<\/i> <\/i>portefeuille<\/i> <\/i>de<\/i> <\/i>produits<\/i> <\/i>de<\/i> <\/i>Tubulis,<\/i> <\/i>de<\/i> <\/i>la<\/i> <\/i>vision<\/i> <\/i>de<\/i> <\/i>son<\/i> <\/i>\u00e9quipe<\/i> <\/i>ainsi<\/i> <\/i>que<\/i> <\/i>de<\/i> <\/i>son<\/i> <\/i>ex\u00e9cution<\/i> <\/i>sans faille. <\/i>Toutes<\/i> <\/i>nos<\/i> <\/i>f\u00e9licitations<\/i> <\/i>\u00e0<\/i> <\/i>l’\u00e9quipe<\/i> <\/i>de<\/i> <\/i>Tubulis<\/i> <\/i>pour<\/i> <\/i>avoir<\/i> <\/i>b\u00e2ti<\/i> <\/i>une<\/i> <\/i>soci\u00e9t\u00e9<\/i> <\/i>ADC<\/i> <\/i>v\u00e9ritablement <\/i>transformatrice et pour<\/i> <\/i>avoir rapproch\u00e9 leurs innovations des<\/i> <\/i>patients \u00bb, <\/i>commente Sofia Ioannidou, <\/b>Associ\u00e9e<\/b> <\/b>chez<\/b> <\/b>Andera<\/b> <\/b>Partners.<\/b><\/p>\n

\u00c0 la cl\u00f4ture de la transaction, Tubulis op\u00e9rera en tant qu’organisation de recherche ADC d\u00e9di\u00e9e au sein de Gilead. Le site de Munich servira de p\u00f4le d’innovation ADC, en s’appuyant sur ses capacit\u00e9s int\u00e9gr\u00e9es de d\u00e9couverte, de fabrication et de d\u00e9veloppement clinique pour faire progresser les ADC de nouvelle g\u00e9n\u00e9ration.<\/p>\n

 <\/p>\n

Termes de la transaction<\/strong><\/p>\n

Aux termes du contrat de cession et d’acquisition, Gilead acquerra la totalit\u00e9 des capitaux propres en circulation de Tubulis pour une contrepartie en num\u00e9raire de 3,15 milliards de dollars \u00e0 la cl\u00f4ture, sur une base sans tr\u00e9sorerie ni dette, sous r\u00e9serve des ajustements habituels, ainsi que jusqu’\u00e0 1,85 milliard de dollars en paiements conditionnels li\u00e9s \u00e0 l’atteinte de jalons. La cl\u00f4ture de la transaction est soumise \u00e0 l’expiration ou \u00e0 la r\u00e9siliation de certains d\u00e9p\u00f4ts r\u00e9glementaires ainsi qu’\u00e0 d’autres conditions habituelles. La transaction devrait \u00eatre finalis\u00e9e au cours du deuxi\u00e8me trimestre 2026. Gilead pr\u00e9voit de financer la transaction par une combinaison de tr\u00e9sorerie disponible et d’obligations senior non garanties (senior unsecured notes).<\/p>\n

Centerview Partners LLC et Allen & Company LLC agissent en tant que conseillers financiers de Gilead. J.P. Morgan Securities LLC agit en tant que conseiller financier exclusif de Tubulis. Covington & Burling LLP, Arnold & Porter LLP et Venable LLP assurent le conseil juridique de Gilead. Goodwin Procter LLP et CMS Hasche Sigle assurent le conseil juridique de Tubulis.<\/p>\n","protected":false},"excerpt":{"rendered":"

Andera Partners annonce aujourd’hui que Gilead Sciences, Inc. (Nasdaq : GILD) a conclu un accord d\u00e9finitif en vue d’acqu\u00e9rir Tubulis GmbH, une soci\u00e9t\u00e9 de biotechnologie priv\u00e9e bas\u00e9e en Allemagne, en phase clinique, sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de conjugu\u00e9s anticorps-m\u00e9dicament (ADC) de nouvelle g\u00e9n\u00e9ration. L’acquisition \u00e9largit consid\u00e9rablement les capacit\u00e9s ADC de Gilead en y int\u00e9grant des…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-93127","post","type-post","status-publish","format-standard","hentry","category-biodiscovery"],"acf":[],"yoast_head":"\nAndera Partners annonce l'acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration. - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners annonce l'acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration. - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners annonce aujourd’hui que Gilead Sciences, Inc. (Nasdaq : GILD) a conclu un accord d\u00e9finitif en vue d’acqu\u00e9rir Tubulis GmbH, une soci\u00e9t\u00e9 de biotechnologie priv\u00e9e bas\u00e9e en Allemagne, en phase clinique, sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de conjugu\u00e9s anticorps-m\u00e9dicament (ADC) de nouvelle g\u00e9n\u00e9ration. L’acquisition \u00e9largit consid\u00e9rablement les capacit\u00e9s ADC de Gilead en y int\u00e9grant des...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T13:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T13:31:09+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners annonce l’acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration.\",\"datePublished\":\"2026-04-07T13:03:00+00:00\",\"dateModified\":\"2026-04-07T13:31:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/\"},\"wordCount\":752,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/\",\"name\":\"Andera Partners annonce l'acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration. - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2026-04-07T13:03:00+00:00\",\"dateModified\":\"2026-04-07T13:31:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners annonce l’acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners annonce l'acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration. - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/","og_locale":"fr_FR","og_type":"article","og_title":"Andera Partners annonce l'acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration. - ANDERA PARTNERS","og_description":"Andera Partners annonce aujourd’hui que Gilead Sciences, Inc. (Nasdaq : GILD) a conclu un accord d\u00e9finitif en vue d’acqu\u00e9rir Tubulis GmbH, une soci\u00e9t\u00e9 de biotechnologie priv\u00e9e bas\u00e9e en Allemagne, en phase clinique, sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de conjugu\u00e9s anticorps-m\u00e9dicament (ADC) de nouvelle g\u00e9n\u00e9ration. L’acquisition \u00e9largit consid\u00e9rablement les capacit\u00e9s ADC de Gilead en y int\u00e9grant des...","og_url":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2026-04-07T13:03:00+00:00","article_modified_time":"2026-04-07T13:31:09+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners annonce l’acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration.","datePublished":"2026-04-07T13:03:00+00:00","dateModified":"2026-04-07T13:31:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/"},"wordCount":752,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/","url":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/","name":"Andera Partners annonce l'acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration. - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2026-04-07T13:03:00+00:00","dateModified":"2026-04-07T13:31:09+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-annonce-lacquisition-de-tubulis-par-gilead-renforcant-son-portefeuille-en-oncologie-avec-un-anticorps-conjuge-adc-potentiellement-best-in-class-et-une-plateforme-de-nouvelle-gener\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Andera Partners annonce l’acquisition de Tubulis par Gilead, renfor\u00e7ant son portefeuille en oncologie avec un anticorps conjug\u00e9 (ADC) potentiellement best-in-class et une plateforme de nouvelle g\u00e9n\u00e9ration."}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/93127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=93127"}],"version-history":[{"count":3,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/93127\/revisions"}],"predecessor-version":[{"id":93132,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/93127\/revisions\/93132"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=93127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=93127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}